Abstract
Objective To investigate the correlation of exosomal miRNA-122 expression with circulating miRNA-122 expression in patients with HCV infection. Methods Twenty four patients with chronic hepatitis C (CHC group), 21 patients with HCV-related liver cirrhosis (LC group), 15 patients with HCV-related hepatocellular carcinoma (HCC group) and 20 healthy subjects (HC group) were enrolled from Hanzhong Central Hospital of Shanxi Province during January 2012 and December 2015. Total RNAs were extracted from exosome in all the subjects. The expressions of miRNA-122 both in exosome and serum were detected by real-time quantitative polymerase chain reaction (qPCR). ANOVA was used to analyze the differences in miRNA-122 expression, and Pearson correlation test was performed to analyze the correlation of exosomal miRNA-122 with circulating miRNA-122. Results Taking exosomal and circulating miRNA-122 expression in healthy control as 1.00, the relative exosomal miRNA-122 expressions in CHC, LC and HCC group were 1.33±0.11, 0.98±0.13, 0.52±0.09, respectively(F=3.316, P<0.05). Exosomal miRNA-122 level in CHC group was higher than that in HC and HCC group (t=4.028 and 9.906, P<0.05), it was higher in LC group than that in HCC group (t=5.631, P<0.05), and it was lower in HCC group than that in HC group significantly (t=5.878, P<0.05). Serum circulating miRNA-122 expressions were 3.66±1.11, 2.88±0.71 and 2.16±0.48 in CHC, LC and HCC group, respectively(F=7.823, P<0.05), the circulating miRNA-122 expression was higher in CHC group than that in HC group (t=4.653, P<0.05). Pearson correlation analysis showed that there was positive correlation between exosomal miRNA-122 level and circulating miRNA-122 level in CHC group (r=0.512, P<0.05), but negative correlation in HCC group (r=-0.223, P<0.05). Conclusions Exosomal miRNA-122 may be used as novel serological biomarkers for detecting chronic hepatitis C and HCV-related HCC. Key words: Hepatitis C antibodies; Serum; Exosome; MicroRNAs-122
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
